![]() ![]() ![]() Revenues Beat: Revenues in the reported quarter also beat expectations. Loss Narrower-Than-Expected: KITE reported second-quarter 2017 loss of 1.94 cents per share, narrower than our consensus estimate of a loss of $1.97 cents per share. We have highlighted some of the key stats from this just-revealed announcement below: It delivered positive earnings surprises in two of the past four quarters and negative surprise in the other two, bringing the average surprise to a positive 2.07%.Ĭurrently, KITE has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. The company has a mixed record of earnings surprises. Kite Pharma is also developing other CAR-based candidates, including KITE-585 and KITE-718. Meanwhile, axicabtagene ciloleucel is also being evaluated in other cancer studies as well. In Europe, a regulatory application was filed last week with an approval and launch expected next year. for treating aggressive non-Hodgkin lymphoma (NHL) with a FDA decision expected on Nov 29.Īxicabtagene ciloleucel is expected to be approved and launched in the U.S this year. Kite Pharma’s lead drug axicabtagene ciloleucel is currently under priority review in the U.S. ![]() Immuno-oncology is a hot therapeutic area with huge commercial potential. The modified T-cells are designed to recognize and destroy cancer cells. Kite uses eACT to genetically modify T cells to express either CARs or TCRs. KITE is a development-stage company focused on the development of immuno-oncology treatments and is looking to revolutionize cancer treatments by engaging the body’s own immune system to treat cancer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |